Comparison of Quetiapine Extended-Release (Seroquel XR) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose, parallel group, non inferiority, 12-week study

Trial Profile

Comparison of Quetiapine Extended-Release (Seroquel XR) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose, parallel group, non inferiority, 12-week study

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Quetiapine (Primary) ; Risperidone
  • Indications Depression; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms ExAttitude
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2014 Results published in the International Clinical Psychopharmacology.
    • 18 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top